Highly aggressive cancers "entrain" innate and adaptive immune cells to suppress antitumor lymphocyte responses. Circulating myeloid-derived suppressor cells (MDSC) constitute the bulk of monocytic immunosuppressive activity in latestage melanoma patients. Previous studies revealed that monocyte-derived macrophage migration inhibitory factor (MIF) is necessary for the immunosuppressive function of tumor-associated macrophages and MDSCs in mouse models of melanoma. In the current study, we sought to determine whether MIF contributes to human melanoma MDSC induction and T-cell immunosuppression using melanoma patient-derived MDSCs and an ex vivo coculture model of human melanoma-induced MDSC. We now report that circulating MDSCs isolated from late-stage melanoma patients are reliant upon MIF for suppression of antigen-independent T-cell activation and that MIF is necessary for maximal reactive oxygen species generation in these cells. Moreover, inhibition of MIF results in a functional reversion from immunosuppressive MDSC to an immunostimulatory dendritic cell (DC)-like phenotype that is at least partly due to reductions in MDSC prostaglandin E 2 (PGE 2 ). These findings indicate that monocyte-derived MIF is centrally involved in human monocytic MDSC induction/ immunosuppressive function and that therapeutic targeting of MIF may provide a novel means of inducing antitumor DC responses in late-stage melanoma patients.
Introduction
Stage IV melanoma is a highly aggressive and resistance-prone malignancy that carries a 5-year survival rate of approximately 15%. Melanoma cells are unusually immunogenic and, consequently, are adept at inducing host innate and adaptive immunosuppressive mechanisms that, collectively, serve to attenuate antitumor lymphocyte responses (1) . Adaptive cell types and effectors involved in melanoma-associated immune suppression include regulatory T lymphocytes (Treg), cytotoxic T lymphocyte antigen-4 (CTLA-4), and programmed cell death 1 (PD-1)-of which the latter two are currently being evaluated as therapeutic targets in late-stage melanoma patients (2) .
It is becoming increasingly evident that tumor-entrained innate immune effector cells-e.g., tumor-associated macrophages (TAM), tumor-associated neutrophils (TAN), tolerogenic dendritic cells (DC), and MDSCs-also provide highly significant degrees of immune escape to aggressive malignancies (3) (4) (5) (6) (7) . In patients with advanced melanoma, circulating monocytic MDSCs provide the bulk of monocyte-associated immune suppression (8) , negatively affect patient survival, and inversely correlate with the presence of functional antigen-specific T cells (9) .
Previous studies from our laboratory established a novel functional role for monocyte-derived macrophage migration inhibitory factor (MIF) in dictating alternative activation phenotypes in mouse melanoma TAMs; loss or inhibition of MIF reduces melanoma TAM-and MDSC-mediated immune suppression (10) . In a related study using the 4T1 mouse model of breast cancer, Simpson and colleagues showed that tumor-derived MIF promotes MDSC accumulation and immunosuppressive activity (11) . Reconstitution of wild-type MIF cDNA into 4T1 MIF shRNA knockdown cells, but not an enzymatically inactive MIF mutant (proline-2 to serine-2, P2S) cDNA, was capable of reconstituting tumor-derived, MIF-dependent MDSC induction. This result was in line with our finding that small-molecule inhibitors of MIF's enzymatic activity fully phenocopy MIF deficiency in their ability to dictate the immunosuppressive activities of monocytes/macrophages in tumor-bearing hosts (10) .
Studies by the Dranoff laboratory have identified MIF as a target of naturally developing auto-antibodies in late-stage melanoma patients who had successfully responded to a trial immunotherapy consisting of autologous GM-CSF secreting tumor cell vaccines followed by CTLA-4 blockade (ipilimumab; ref. 12) . MIF auto-antibodies disrupted MIF-dependent effects on human monocytes/macrophages, suggesting that the beneficial effects of these MIF-targeting auto-antibodies in advanced melanoma patients are due to inhibition of MIF-dependent innate immune stromal cell phenotypes. Although this finding suggests a clinically relevant role for MIF in human melanoma disease progression/survival, no studies have directly investigated the functional and/or mechanistic contributions of MIF to innate immune cell-mediated immune suppression in melanoma patients.
Using our well-characterized, small-molecule MIF enzymatic antagonist (4-iodo-6-phenylpyrimidine, 4-IPP; refs. 10, 13-15), we investigated MIF contributions to human melanoma MDSC induction, phenotype, differentiation status, and mechanistic effectors. We show that human MDSCs derived from late-stage melanoma patients and those induced in vitro by tumor cells rely on MIF to suppress T-cell activation. MIF reliance corresponds with reactive oxygen species (ROS) and cyclooxygenase-2 (COX-2)/PGE 2 production elicited by MDSCs. Unexpectedly, when MDSC-derived MIF is inhibited during short-term ex vivo culture of MDSCs, their differentiation is redirected toward a more DClike phenotype. These MIF-inhibited monocytic MDSCs induce antigen-specific T-cell stimulatory function in these cells.
Together, our results support a crucial protumorigenic contribution by MIF to the immune suppression and differentiation of circulating melanoma MDSCs and provide justification for therapeutic targeting of MIF in patients with advanced melanoma disease.
Materials and Methods

Patient samples and cell lines
Peripheral blood was collected from 27 patients with metastatic melanoma stage III to IV, and from 12 healthy donors. Melanoma patients included in this study were not undergoing therapy when their samples were collected, and they all had progressive disease. Patient samples were collected after informed consent was obtained by staff of the JG Brown Cancer Center Biorepository and covered under University of Louisville IRB protocol number 08.0388. The melanoma cell line A375 (ATCC CRL-1619) was purchased from ATCC and maintained in DMEM containing 10% (v/v) FBS. We do not culture this cell line longer than 6 to 8 weeks, and all of our stocks come from thawed vials that were frozen at passage 2 after they were received from ATCC. The A375 cell line was authenticated by the ATCC cell bank using short tandem repeat profiling.
Mice
Wild-type male C57BL/6 mice (MIF þ/þ ) were obtained from Harlan Laboratories. OT-I and OT-II transgenic mice were obtained from The Jackson Laboratory. All mice were handled with the approval of the Institutional Animal Care and Use Committee at the University of Louisville (Louisville, KY).
MDSC isolation and 4-IPP treatment
Monocytic CD14 þ MDSCs from melanoma patients were isolated from peripheral blood mononuclear cells (PBMC) using anti-CD14 magnetic microbeads and the autoMACS Pro Separator (Miltenyi Biotec), per manufacturer's instructions. One million MDSCs were plated in complete Iscove's modified Dulbecco's medium (IMDM; supplemented with 10% human AB serum; Sigma-Aldrich; 2 mmol/L L-glutamine, and penicillin/ streptomycin) per well in a 6-well plate (BD Falcon) and treated with 4-IPP (50 mmol/L) or DMSO (vehicle control) for 24 hours.
For functional experiments, autologous T cells were isolated from PBMCs using the Pan T-cell Isolation Kit (Miltenyi Biotec).
In vitro generation of human MDSCs CD14 þ cells (1 Â 10 6 ) isolated from PBMCs obtained from healthy donors were cocultured with 5 Â 10 5 A375 tumor cells in complete IMDM per well in a 6-well plate (16) . Tumor/monocyte cocultures were treated twice with 4-IPP (100 mmol/L on day 0 and 50 mmol/L on day 2) or 0.1% DMSO (vehicle control). A375 cocultured monocytes (both untreated and 4-IPP treated) and control monocytes cultured without tumor cells were harvested by gently scraping after 64 to 68 hours of culture and CD11b þ cells were purified. Details for cell isolation techniques used are provided in the Supplemental Methods section.
Mouse bone marrow-derived MDSCs
Tibias and femurs from MIF þ/þ and MIF À/À C57BL/6 mice were removed using sterile techniques, and bone marrow was flushed.
To obtain bone marrow-derived MDSCs, bone marrow cells were cultured for 4 days with GM-CSF (40 ng/mL), and IL6 (40 ng/mL) cytokines, as previously described (17) . MIF þ/þ and MIF À/À bone marrow cultures were treated with 0.1% DMSO (vehicle control) or with 4-IPP (50 mmol/L) during the last 48 hours of the culture period. For functional assays, CD11b
MDSCs were isolated from bone marrow cultures using CD11b and GR1 microbeads followed by magnetic separation (Miltenyi).
Antibodies and flow cytometry Untreated or 4-IPP-treated melanoma patient MDSCs and tumor cell line-induced MDSCs (A375-MDSC) were stained with anti-human antibodies according to the manufacturer's recommendations. Details on flow cytometry staining and antibody panels are provided in the Supplemental Methods section and in Supplementary Table S1 .
Functional studies
To Quantitative PCR analysis Total RNA and real-time analysis was performed as previously described (10) . Taqman probes (Applied Biosystems) for genes 18S (Hs99999901.s1; VIC), MIF (Hs00236988_g1; FAM), COX-2 (Hs00153133_m1; FAM), and NOX4 (Hs00418356_m1; FAM) were used according to the manufacturer's instructions.
Microarray analysis
Total RNA from cultured monocytes, vehicle-treated, and 4-IPP-treated A375-MDSCs were isolated, and microarray analysis was performed according to the manufacturer's instructions. Details of the instrumental set-up and analysis are described in the Supplemental Methods section. The microarray datasets discussed in the current study have been deposited in NCBI's Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo) and are accessible through GEO Series accession number GSE73333.
ROS detection
The oxidation-sensitive dye DCF-DA was used to measure ROS production in untreated or 4-IPP-treated melanoma patient MDSCs or A375-MDSCs. Details of ROS estimation by flow cytometry are provided in the Supplemental Methods section.
Western blotting
Lysates of cultured monocytes and A375-MDSCs were probed with antibodies that recognize human MIF and human GAPDH (Santa Cruz Biotechnology, Inc.).
ELISAs
Cytokines were measured by ELISA in supernatants from T-cell: MDSC cocultures and from MDSC cultures. ELISA kits used were the human IFNg and PGE 2 kits obtained from R&D Systems.
Statistical analysis
GraphPad Prism 5.0 software (GraphPad Prism Software, Inc.) was used for all statistical analyses. Two-group comparisons between control and test samples (groups compared are indicated in the respective figures) were done by two-tailed Student t tests. Multiple data comparisons were derived by one-way ANOVA followed by the Tukey post hoc test. For all tests, statistical significance was assumed where P < 0.05.
Results
Circulating CD14
þ HLADR À/low MDSCs with potent immunoregulatory activities have been identified in the peripheral blood of patients with ovarian cancer (18) , hepatocellular cancer (19) , and late-stage melanoma (20) (21) (22) . In an effort to extend our previous findings that monocytic cell-derived MIF provides functional contributions to MDSC immunosuppressive activity (10), we first analyzed the frequency and phenotype of circulating monocytic MDSCs in stage III/IV metastatic melanoma patients using multicolor FACS analysis. Representative dot plots for one of the melanoma patients and one of the normal donors are included in the study to illustrate the gating strategy used (Fig. 1A) . The percentage of circulating lineage
þ HLADR À/low monocytic MDSCs is significantly elevated in melanoma patients' freshly isolated peripheral blood compared with that in normal donors ( Fig. 1A and B ; refs. 21, 22) . Consistent with prior studies (21, 22) , in our study purified CD14 þ melanoma monocytes exhibited potent inhibitory activity against autologous T-cell activation ( Fig. 2A and B) and IFNg production ( Fig. 2C ) induced by anti-CD3/anti-CD28, compared with cultured CD14 þ monocytes from normal donors ( Fig. 2D-F ). This finding is also consistent with prior studies (8) To determine whether MIF inhibition during MDSC induction influences the acquisition of MDSC phenotype/function, 4-IPP was added at the beginning of the A375:monocyte coculture. Changes in cell-surface marker expression of A375-MDSCs and relative T-cell suppressive activity were assessed 68 hours later. MIF inhibition during the MDSC induction phase by melanoma cells resulted in reductions of CD14, CD33, and PD-L1 and an increase in DC-SIGN expression, whereas HLA-DR or CD11c expression was not significantly altered (Supplementary Figs. S3A and S3B).
With respect to functional immunosuppressive activities, A375-MDSCs were potent suppressors of autologous T-cell activation and IFNg production compared with fresh monocytes and tumor cell-free cultured monocytes, whereas A375-MDSCs from 4-IPP-treated cocultures (A375-MDSCs þ 4-IPP) possessed little to no suppressive activity on T-cell proliferation/IFNg production (Fig. 3) . The induction of suppressive function in monocytes relied upon direct cell contact with the tumor cells: Monocytes cultured in the presence of A375 tumor cell-conditioned media did not suppress autologous T-cell activation ( Supplementary  Fig. S4A ). This finding is consistent with previous observations using the same A375-monocyte coculture model system to induce MDSCs (16) . To evaluate whether the diminished suppressive activity observed with MDSCs from 4-IPP-treated A375-monocyte cocultures was simply due to a reduced number of MDSCs present in the 4-IPP-treated cultures, we isolated CD11b To validate these observations, we turned to a murine in vitro model of bone marrow-derived MDSC induction using GM-CSF and IL6 (17) . Similar to 4-IPP treatment during the induction of human MDSCs by a melanoma cell line (Fig. 3) , murine bone marrow MDSCs from MIF-deficient mice were significantly less immunosuppressive than their wild-type counterparts ( Supplementary Fig. S6C ). MIF-deficient bone marrow MDSCs expressed less of the prototypical murine MDSC marker GR1 and more CD11c when compared with bone marrow MDSCs derived from MIF wild-type mice-a finding suggestive of a broader defect in MDSC induction associated with loss of MIF ( Supplementary Fig. S6A and S6B ). To rule out the possibility that the lower suppressive activity observed with MIF-deficient bone marrow MDSCs was not simply due to fewer MDSCs present in the differentiated MIF-deficient bone marrow MDSCs, we isolated CD11b þ GR1 þ MDSCs from both MIF wild-type and MIF-deficient bone marrow cultures and compared their immunosuppressive functions. CD11b
MDSCs from wild-type bone marrow MDSCs exhibited potent inhibitory activity on antigen-specific T-cell proliferation, compared with Fig. 7A ), confirming the lack of any residual in vitro 4-IPP activity in the absence of its target, MIF. 
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To identify potential mechanistic effectors and/or pathways associated with melanoma monocytic MDSCs, we performed mRNA microarray analyses on cultured monocytes and on A375-MDSCs obtained from either untreated or 4-IPP-treated A375:monocyte cocultures. Expression profiles from A375-MDSCs were markedly different from those for cultured monocytes ( Supplementary Fig. S8A ).
When MIF was inhibited during A375-MDSC induction, a large subset of gene products reverted back to levels observed in monocytes cultured in the absence of tumor cells ( Supplementary  Fig. S8B ). Inflammatory cytokines, chemokines/chemokine receptors, matrix metalloproteases, angiogenic growth factors and arachidonic acid/prostaglandin-generating enzymes were all differentially expressed in A375-MDSCs and restored to "normal" expression by MIF inhibition (Supplementary Fig. S8C ).
One gene product of particular interest is that of the NADPH oxidase 4 enzyme (NOX4; Supplementary Fig. 8C ). Because NADPH oxidases are centrally involved in mediating MDSC immunosuppressive activities (21, 24), we next validated by qPCR that NOX4 is induced in A375-MDSCs, but not in A375-MDSCs from 4-IPP-treated cocultures (Fig. 4A) . NADPH oxidases convert molecular oxygen into superoxide anion upon activation by protein kinase 3 (25), so we next evaluated the relative ability of phorbol myristic acid (PMA) to induce dichlorofluorescein (DCF)-detectable ROS in A375-MDSCs. DCF fluorescence was more strongly induced by PMA in A375-MDSCs than in A375-MDSCs obtained from 4-IPP-treated cocultures (Figs. 4B and C) . In accordance with published results (21), CD14 þ monocytes from freshly isolated PBMC from melanoma patients had more ROS than healthy donor CD14 þ monocytes ( Supplementary Fig.   S1C ), and treatment of isolated melanoma MDSCs with 4-IPP for 24 hours significantly reduced DCF-detectable ROS in these cells ( Fig. 4D and E) . Murine MDSCs, when cultured in the presence of appropriate growth factors, can differentiate into DCs (26, 27) . Human melanoma MDSCs are characterized by higher levels of the DC markers, CD80, CD83, and DC-SIGN compared with normal human monocytes (21) . Short-term, cytokine-free culture of human melanoma MDSCs moderately increases the expression of DC markers-including and especially HLA-DR-but without loss of CD14 expression. The retention of CD14 expression on these cells is indicative of a lack of lineage-specific differentiation 
(21).
In an effort to determine whether MIF inhibition influences MDSC ! DC differentiation phenotypes, purified MDSCs from melanoma patients were cultured in the presence and absence of 4-IPP for 72 hours (Fig. 5) . Treatment with 4-IPP resulted in significant increases in the percentage of cells (Fig. 5B, top) and relative expression (MFI; Fig. 5B , bottom) of DC markers CD80, CD83, CD86, CD40, and perhaps more importantly, significant reductions in CD14 and PD-L1 on HLA-DR þ MDSCs.
We next sought to recapitulate these findings using MDSCs derived from the A375:monocyte coculture model. We tested two independent models (please see the diagram, Supplementary Supplementary Fig. S9C ). Changes in DC marker upregulation were similar, whether 4-IPP was added during MDSC induction (A375-MDSC þ 4-IPP) or after MDSC induction (A375-MDSCs treated with 4-IPP) compared with control, untreated A375-MDSCs (Fig. 6A) . Specifically, markers associated with DCs-CD80, CD83, CD40, CD1A, CD86, and CD11c-showed a trend toward increased expression in both 4-IPP treatment conditions of HLA-DR þ A375-MDSCs, although not all conditions resulted in statistically significant increases (Fig. 6A ).
To determine whether these phenotypic marker changes correspond to an increase in antigen-specific T-cell functional responses, established A375-MDSCs were cultured with or without 4-IPP for 72 hours (per Supplementary Fig. S9C ) followed by assessment of tetanus toxoid-induced T-cell activation. Neither normal donor-cultured monocytes (Mono:T) nor untreated A375-MDSCs could induce tetanus toxoid-specific T-cell activation to any appreciable extent ( Fig. 6B and C) . In contrast, 4-IPPtreated A375-MDSCs induced an approximately 4-fold increase in tetanus toxoid-specific T-cell proliferation, indicating that MIF inhibition promotes established MDSC differentiation that results in antigen-specific T-cell responses.
We next validated these findings in the murine MIF-deficient model, using bone marrow MDSCs. Like human melanoma MDSCs treated with 4-IPP, murine MIF-deficient bone marrow MDSCs cultured for 48 hours in cytokine-free media express elevated CD80, CD83, CD86, and MHC II-IA-IE compared with MIF wild-type bone marrow MDSCs ( Supplementary Fig. S10A and S10B). These MIF-deficient bone marrow MDSCs could induce ovalbumin-specific CD4 þ T-cell proliferation to a significantly greater extent than bone marrow MDSCs from MIF wild-type mice ( Supplementary Fig. S10C and S10D ). Together, these findings indicate that loss or inhibition of MIF promotes MDSC differentiation toward a more DC-like cell phenotype that results in noticeably improved T cell-mediated antigen-specific immune responses. Prostaglandin E 2 (PGE 2 ) is a critical determinant of MDSC immunosuppressive activity and, perhaps more importantly, can redirect the differentiation of human DC toward functionally stable MDSCs (16, 28, 29) . PGE 2 is generated from a prostaglandin synthase 2 (PTGS2, aka COX-2)-dependent conversion of arachidonic acid (released as a product of phospholipase A 2 catalysis) to PGH 2 , which is then converted to PGE 2 by prostandin E synthase (PTGES). Because the expression of cytosolic PLA 2 (PLA2G4), COX-2 (PTGS2), and PTGES are all increased in A375-MDSCs in an MIF-dependent manner ( Supplementary Fig. S8C ), we next sought to determine whether reductions in PGE 2 in 4-IPP-treated melanoma MDSCs were mechanistically linked to MDSC differentiation toward DC-like cells.
As COX-2 is generally considered to be the rate-limiting step associated with PGE 2 production and release, we first determined whether COX-2 expression is elevated in MDSCs from patients with late-stage melanoma. The average mRNA expression of COX-2 in peripheral blood CD14 þ cells isolated from advanced melanoma patients (n ¼ 5) was approximately 10-fold greater than that of CD14 þ cells isolated from normal donors (n ¼ 5; Fig. 7A ). Inhibition of MIF with 4-IPP in both patient-derived MDSCs (Fig. 7B ) and A375-MDSCs (Fig. 7C ) significantly reduced COX-2 mRNA expression, consistent with several studies that demonstrated a central regulatory role for MIF in dictating COX-2 expression (30-32). The reduced COX-2 expression in melanoma patient-derived MDSCs treated with 4-IPP established that both A375-MDSCs and A375: monocyte cocultures correlated with significant reductions in PGE 2 concentrations (Fig. 7D-F) . Next, we asked whether reconstituting PGE 2 to 4-IPP-treated MDSC cultures was sufficient to reverse the effects of MIF inhibition on MDSC ! DC-like differentiation ( Fig. 7G and H) . (33, 34) . In cancer patients, defective DCs have been implicated in promoting tumor growth and adversely affecting antitumor efficacy of vaccines. Inhibition of VEGF signaling with VEGF-Trap treatment improves DC differentiation/maturation in cancer patients; these effects, however, are insufficient to improve antigen-specific immune responses (35) . This lack of immune response is linked to the increased presence of MDSCs in the peripheral blood of the treated patients. Our findings that a safe, bioavailable, and highly efficacious in vivo pharmacologic MIF inhibitor is sufficient to induce MDSC differentiation into functionally immunostimulatory DCs suggest that a multifaceted approach combining anti-MIF therapeutics with established DC maturation strategies could be highly effective in the treatment of late-stage cancer patients (35) .
Although several studies describe important functional contributions by MIF to murine innate immune tumor stromal cell phenotypes, none of these previous studies-including our own (10)-have identified mechanistic effectors and signaling pathways of MIF-dependent functions (11, 36) . In an attempt to 
